Clinical Trials Directory

Trials / Completed

CompletedNCT01408498

Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
120 (actual)
Sponsor
University of Texas at Austin · Academic / Other
Sex
Male
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

The study aims to establish a clear causal link between testosterone and threat perception and behavioral responses to threat. Namely, the study focuses whether high levels of testosterone will cause an individual to exhibit increased physiological responses to threat (e.g., increased blood pressure, heart rate, and endocrine responses) and a decreased behavioral response (e.g., ignoring the threat, avoiding the threat, and postponing dealing with the threat). The threat in this study is a social threat involving public speaking, and is an outgrowth of previous research on the avoidance of health threats.

Detailed description

Participants in the study will receive either a single dose of 10g 1% testosterone topical gel or placebo the day prior to participating in the study. The day of the study, participants will provide saliva samples throughout the study to track testosterone and cortisol levels. Participants will be asked to complete the Trier Social Stressor Task, which includes having to give a 5 minute speech to a panel of judges. Participants will be given the opportunity to postpone giving their speech to an unspecified date. The study will focus on two types of responses to the threat of public speaking: behavioral and physiological. The behavior of interest will be participants desire to postpone dealing with the threat (it is hypothesized that those in the testosterone administration group will have an increased desire to postpone). The physiological responses include increased levels of cortisol and increased cardiovascular tone (it is hypothesized that the testosterone administration group will show an increased physiological response compared to the placebo group).

Conditions

Interventions

TypeNameDescription
DRUGTestosteroneTopical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.

Timeline

Start date
2012-01-01
Primary completion
2012-04-01
Completion
2012-04-01
First posted
2011-08-03
Last updated
2012-10-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01408498. Inclusion in this directory is not an endorsement.